Did the decrease in use of menopausal hormone therapy induce a decrease in the incidence of breast cancer in France (and elsewhere)?;La diminution de l'utilisation du traitement hormonal de la ménopause a-t-elle fait baisser l'incidence du cancer du sein en France (et ailleurs) ?

Revue d'Epidemiologie et de Sante Publique

Volumn 56, Issue 5, 2008, Pages 297-301

  Ringa, V ^a,b,c   Fournier, A ^b  

^a INSTITUT NATIONAL D'ÉTUDES DÉMOGRAPHIQUES   (France)

^b INSERM   (France)

^c UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ARTICLE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER SCREENING; CHEMOPROPHYLAXIS; ESTROGEN THERAPY; FRANCE; HUMAN; MAMMOGRAPHY; POSTMENOPAUSE; RISK BENEFIT ANALYSIS; RISK REDUCTION; WOMEN'S HEALTH; AGE DISTRIBUTION; ALCOHOL CONSUMPTION; BEHAVIORAL RISK FACTOR SURVEILLANCE SYSTEM; BODY MASS; CANCER REGISTRY; RISK FACTOR; SCREENING TEST; WORLD HEALTH ORGANIZATION;

AGE FACTORS; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTILIPEMIC AGENTS; BREAST NEOPLASMS; CALIFORNIA; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; EUROPE; FEMALE; FRANCE; HUMANS; INCIDENCE; MENOPAUSE; MIDDLE AGED; POSTMENOPAUSE; PREVALENCE; PROGESTINS; RISK FACTORS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 55549107119     PISSN: 03987620     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.respe.2008.07.085     Document Type: Article

References (33)

1. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 288 (2002) 321-333
2. Collins J.A., Blake J.M., and Crosignani P.G. Breast cancer risk with postmenopausal hormonal treatment. Hum Reprod Update 11 (2005) 545-560
3. Fournier A., Berrino F., and Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: Results from the E3N cohort study. Breast Cancer Res Treat 107 (2008) 103-111
4. Allemand H., Seradour B., Weill A., and Ricordeau P. Decline in breast cancer incidence in 2005 and 2006 in France: A paradoxical trend. Bull Cancer 95 (2008) 11-15
5. Dietel M., Lewis Ma, and Shapiro S. Hormone replacement therapy: Pathobiological aspects of hormone-sensitive cancers in women relevant to epidemiological studies on HRT: A mini-review. Hum Reprod 20 (2005) 2052-2060
6. Ravdin P.M., Cronin K.A., Howlader N., et al. The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med 356 (2007) 1670-1674
7. Beral V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362 (2003) 419-427
8. Krieger N. Hormone therapy and the rise and perhaps fall of US breast cancer incidence rates: Critical reflections. Int J Epidemiol 37 (2008) 627-637
9. Lawson D.H., Jick H., Hunter Jr., and Madsen S. Exogenous estrogens and breast cancer. Am J Epidemiol 114 (1981) 710-713
10. Clarke C.A., and Glaser S.L. Declines in breast cancer after the WHI: Apparent impact of hormone therapy. Cancer Causes Control 18 (2007) 847-852
11. Keegan T.H., Chang E.T., John E.M., et al. Recent changes in breast cancer incidence and risk factor prevalence in San Francisco Bay area and California women: 1988 to 2004. Breast Cancer Res 9 (2007) R62
12. Patani N., Jouhra F., and Mokbel K. Changes in breast cancer incidence rates. Cancer Epidemiol Biomarkers Prev 17 (2008) 742
13. Jemal A., Ward E., and Thun M.J. Recent trends in breast cancer incidence rates by age and tumor characteristics among U.S. women. Breast Cancer Res 9 (2007) R28
14. Katalinic A., and Rawal R. Decline in breast cancer incidence after decrease in utilisation of hormone replacement therapy. Breast Cancer Res Treat 107 (2008) 427-430
15. Huot L., Couris C.M., Tainturier V., Jaglal S., Colin C., and Schott A.M. Trends in HRT and anti-osteoporosis medication prescribing in a European population after the WHI study. Osteoporos Int 19 (2008) 1047-1054
16. Mc Neil C. Breast cancer decline mirrors fall in hormone use, spurs both debate and research. J Natl Cancer Inst 99 (2007) 266-267
17. Jordan V.C. The rise of raloxifene and the fall of invasive breast cancer. J Natl Cancer Inst 100 (2008) 831-833
18. Castrellon A.B., and Gluck S. Chemoprevention of breast cancer. Expert Rev Anticancer Ther 8 (2008) 443-452
19. Bonovas S., Filioussi K., Tsavaris N., and Sitaras N.M. Use of statins and breast cancer: A meta-analysis of seven randomized clinical trials and nine observational studies. J Clin Oncol 23 (2005) 8606-8612
20. Agrawal A., and Fentiman I.S. NSAIDs and breast cancer: A possible prevention and treatment strategy. Int J Clin Pract 62 (2008) 444-449
21. Guay M.P., Dragomir A., Pilon D., Moride Y., and Perreault S. Changes in pattern of use, clinical characteristics and persistence rate of hormone replacement therapy among postmenopausal women after the WHI publication. Pharmacoepidemiol Drug Saf 16 (2007) 17-27
22. Wysowski D.K., and Governale L.A. Use of menopausal hormones in the United States, 1992 through June, 2003. Pharmacoepidemiol Drug Saf 14 (2005) 171-176
23. Kerlikowske K., Miglioretti D.L., Buist D.S., Walker R., and Carney P.A. Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 99 (2007) 1335-1339
24. Chlebowski R.T., Hendrix S.L., Langer R.D., et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative randomized trial. JAMA 289 (2003) 3243-3253
25. Clarke C.A., Glaser S.L., Uratsu C.S., Selby J.V., Kushi L.H., and Herrinton L.J. Recent declines in hormone therapy utilization and breast cancer incidence: Clinical and population-based evidence. J Clin Oncol 24 (2006) e49-50
26. Bouchardy C., Morabia A., Verkooijen H.M., Fioretta G., Wespi Y., and Schafer P. Remarkable change in age-specific breast cancer incidence in the Swiss canton of Geneva and its possible relation with the use of hormone replacement therapy. BMC Cancer 6 (2006) 78
27. Soerjomataram I., Coebergh J.W., Louwman M.W., Visser O., and Van Leeuwen F.E. Does the decrease in hormone replacement therapy also affect breast cancer risk in the Netherlands?. J Clin Oncol 25 (2007) 5038-5039 author reply 5039-40
28. Vaidya J.S. Re: Declines in invasive breast cancer and use of postmenopausal hormone therapy in a screening mammography population. J Natl Cancer Inst 100 (2008) 598-599 author reply 599
29. Zahl P.H., and Maehlen J. A decline in breast-cancer incidence. N Engl J Med 357 (2007) 510-511 author reply 513
30. Buist D.S., Newton K.M., Miglioretti D.L., et al. Hormone therapy prescribing patterns in the United States. Obstet Gynecol 104 (2004) 1042-1050
31. Robbins A.S., and Clarke C.A. Regional changes in hormone therapy use and breast cancer incidence in California from 2001 to 2004. J Clin Oncol 25 (2007) 3437-3439
32. Glass A.G., Lacey Jr. J.V., Carreon J.D., and Hoover R.N. Breast cancer incidence, 1980-2006: Combined roles of menopausal hormone therapy, screening mammography and estrogen receptor status. J Natl Cancer Inst 99 (2007) 1152-1161
33. Verkooijen H.M., Koot V.C., Fioretta G., et al. Hormone replacement therapy, mammography screening and changing age-specific incidence rates of breast cancer: An ecological study comparing two European populations. Breast Cancer Res Treat 107 (2008) 389-395